(BPT) - For the hundreds of thousands of Americans who undergo heart bypass surgery each year, the relief of surviving such a major procedure is often shadowed by one sobering fact: The risk of another heart attack or stroke still lingers.

Bypass surgery reroutes blood flow around blocked arteries, but it doesn't stop the underlying disease; atherosclerosis, the buildup of plaque and inflammation inside artery walls. This process continues even after surgery, keeping the danger alive. Now, groundbreaking new research shows that adding a small daily pill - low-dose colchicine, 0.5 mg - can make a life-saving difference.

A breakthrough in post-bypass care

In a newly published study, researchers found that patients who added low-dose colchicine to their standard therapy after bypass surgery experienced significantly fewer serious cardiovascular events. The findings are striking: if all 150,000 Americans who undergo bypass each year were treated with low-dose colchicine, it could prevent more than 8,000 heart attacks, 16,000 strokes and nearly 10,000 repeat procedures over five years.

That's not just statistics - that's tens of thousands of families spared the trauma of watching a loved one rushed back to the hospital for another life-threatening event.

The study's authors also noted that bypass patients remain at risk for long-term plaque buildup. Early evidence suggests this ongoing process of atherosclerosis may also be reduced by low-dose colchicine, 0.5 mg - offering patients protection well beyond the immediate recovery period.

Why inflammation matters

Most people know high cholesterol can increase the risk of heart disease. But what's less understood is the role of inflammation in fueling atherosclerosis.

According to Johns Hopkins Medicine, plaque buildup (atherosclerosis) in arteries can trigger inflammation, creating a dangerous cycle of more plaque and increased risk of heart attacks or strokes. If left untreated, this chronic inflammation can damage healthy tissue like arteries and the heart itself. Doctors sometimes describe it as a "slow-burning fire" inside the arteries - invisible but steadily damaging the heart.

Expert insight

"The research makes it clear that post-bypass treatment must address inflammation in addition to cholesterol," said Jimmy Kerrigan, M.D., FSCAI, FACC, assistant professor of Medicine at the University of Tennessee Health Science Center and interventional cardiologist at Saint Thomas Heart at Ascension Saint Thomas West in Nashville, Tennessee. "For patients already taking a statin, adding low-dose colchicine, 0.5 mg daily, has been proven to significantly reduce the risk of life-threatening events like stroke and heart attack."

Three tests that reveal hidden risk

Even if you've never had a heart attack or bypass, there are three simple blood tests that can give you and your doctor a clearer picture of your heart health:

• LDL cholesterol: the "bad" cholesterol most patients already track.
• Lipoprotein(a): a genetic risk factor not usually measured in routine checkups.
• High-sensitivity C-reactive protein (hs-CRP): a marker of inflammation that many patients don't even know exists.

For bypass patients in particular, hs-CRP can reveal whether dangerous inflammation, the very process driving atherosclerosis, is still smoldering inside the arteries. If your hs-CRP levels show ongoing inflammation, your doctor may recommend adding low-dose colchicine, 0.5 mg - currently the only anti-inflammatory treatment approved to reduce cardiovascular risk - to better protect against future events.

A call to action

If you or someone you love has had a heart bypass, don't wait for another crisis to strike. Talk to your doctor about whether adding low-dose colchicine, 0.5 mg daily, could help protect against the hidden threat of atherosclerosis and inflammation.

To learn more about cardiovascular inflammation and to check your risk using a quick online quiz, visit CVDInflammation.com.

Indication:

Low-dose colchicine, 0.5 mg is indicated to reduce the risk of myocardial infarction (heart attack), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.

LODOCO-PM-DP-092325-01-01